

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

RESULTS OF THE REPURCHASE OF A SHARES

Reference is made to the circular (the “**Circular**”) dated 6 March 2020 and the announcements dated 5 March 2020, 2 April 2020, 6 May 2020, 1 June 2020, 2 July 2020, 3 August 2020, 1 September 2020, 9 October 2020, 2 November 2020 and 1 December 2020 of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries, the “**Group**”) in relation to the Repurchase of Part of the Public Shares Scheme. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

2 April 2020, the Company repurchased A Shares of the Company through centralized bidding transactions for the first time. The Repurchase Period of the Repurchase Scheme expired on 25 December 2020, and the Repurchase Scheme was completed. During the Repurchase Period, the Company made a total repurchase of 6,093,808 A Shares of the Company (the “**Repurchased A Shares**”) through centralized bidding transactions, accounting for 0.64% of the total issued share capital (944,814,571 shares) and 0.98% of the total number of issued A Shares (624,950,354 shares) of the Company on 25 December 2020. The highest purchase price was RMB44.88 per share and the lowest purchase price was RMB38.95 per share. Total amount of funds used was RMB250,061,413.16 (including transaction costs) and RMB250,011,381.23 (excluding transaction costs). The share repurchase mentioned above complies with the Repurchase Scheme.

The Repurchased A Shares will be cancelled and the Company will reduce its registered capital accordingly. The Company will apply for the cancellation of the Repurchased A Shares to Shenzhen Stock Exchange and Shenzhen Branch of China Securities Depository and Clearing Corporation Limited as soon as possible, and will go through relevant registration formalities of the change in time after completion of the cancellation.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China
28 December 2020

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Zheng Zhihua, Mr. Xie Yun, Mr. Tian Qiusheng and Mr. Wong Kam Wa.

** For identification purpose only*